|
[1]GUAN YS, ZI L, LIN Y, et al.p53 gene in treatment of hepatic carcinoma:Status quo[J].World J Gastroenterol, 2007, 13 (7) :985-992.
|
|
[2]DELBRIDGE AR, STRASSER A.The BCL-2 protein family, BH3-mimetics and cancer therapy[J].Cell Death Differ, 2015, 22 (7) :1071-1080.
|
|
[3]ZHENG JH, VIACAVA FOLLIS A, KRIWACKI RW, et al.Discoveries and controversies in BCL-2 protein-mediated apoptosis[J].FEBS J, 2016, 283 (14) :2690-2700.
|
|
[4]WANG B, NI ZH, DAI XF, et al.The Bcl-2/x L inhibitor ABT-263increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells[J].Mol Cancer, 2014, 13:98.
|
|
[5]ZHAO X, OGUNWOBI OO, LIU C.Survivin inhibition is critical for Bcl-2 inhibitor-induced apoptosis in hepatocellular carcinoma cells[J].PLo S One, 2011, 6 (8) :e21980.
|
|
[6]DENG X, WU JB.Updates in the research of relationship between MicroRNAs and hepatocellular carcinoma[J].Chin J Dig Surg, 2015, 14 (5) :431-433. (in Chinese) 邓曦, 吴敬波.微RNAs与肝癌关系的研究进展[J].中华消化外科杂志, 2015, 14 (5) :431-433.
|
|
[7]POLLUTRI D, GRAMANTIERI L, BOLONDI L, et al.TP53/MicroRNA interplay in hepatocellular carcinoma[J].Int J Mol Sci, 2016, 17 (12) :2029.
|
|
[8]WANG YQ, WU LB, CHEN F.Effects of miR-10b on the proliferation, invasion and migration of hepatocellular carcinoma cells[J].China Med Herald, 2016, 13 (34) :25-29. (in Chinese) 王勇强, 吴林波, 陈帆.miR-10b对肝癌细胞增殖、侵袭和迁移的影响[J].中国医药导报, 2016, 13 (34) :25-29.
|
|
[9]YANG YL, LIU WR, DING RF, et al.Comprehensive expression profiling and functional network analysis of p53-regulated MicroR-NAs in Hep G2 cells treated with doxorubicin[J].PLo S One, 2016, 11 (2) :e0149227.
|
|
[10]FORNARI F, MILAZZO M, GALASSI M, et al.p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma[J].Mol Cancer Res, 2014, 12 (2) :203-216.
|
|
[11]HU J, XU YX, HAO JL, et al.miR-122 in hepatic function and liver diseases[J].Protein Cell, 2012, 3 (5) :364-371.
|
|
[12]SENTURK S, MUMCUOGLU M, GURSOY-YUZUGULLU O, et al.Transforming growth factor-beta induces senescence in hepatocellular carcinoma cells and inhibits tumorgrowth[J].Hepatology, 2010, 52 (3) :966-974.
|
|
[13]GIANNELLI G, MIKULITS W, DOOLEY S, et al.The rationale for targeting TGF-βin chronic liver diseases[J].Eur J Clin Invest, 2016, 46 (4) :349-361.
|
|
[14]MORRIS SM, BAEK JY, KOSZAREK A, et al.TGFβsignaling promotes hepatocarcinogenesis induced by p53 loss[J].Hepatology, 2012, 55 (1) :121-131.
|
|
[15]FAN GL, YAO Y, YAO L, et al.PDCD5 transfection increases cisplatin sensitivity and decreases invasion in hepatic cancer cells[J].Oncol Lett, 2015, 9 (1) :411-417.
|
|
[16]KUO KK, JIAN SF, LI YJ, et al.Epigenetic inactivation of transforming growth factor-β1 target gene HEYL, a novel tumor suppressor, is involved in the P53-induced apoptotic pathway in hepatocellular carcinoma[J].Hepatol Res, 2015, 45 (7) :782-793.
|
|
[17]MOUDGIL V, REDHU D, DHANDA S, et al.A review of molecular mechanisms in the development of hepatocellular carcinoma by aflatoxin and hepatitis B and C viruses[J].J Environ Pathol Toxicol Oncol, 2013, 32 (2) :165-175.
|
|
[18]ESKANDER EF, YAHYA SM, SHAKER OG.P53 codon 72 single base substitution in viral hepatitis C and hepatocarcinoma incidences[J].Ind J Clin Biochem, 2014, 29 (1) :3-7.
|
|
[19]FENG SH, LI M, ZHANG JQ, et al.Regulation of Hep G2 cell apoptosis by hepatitis C virus (HCV) core protein via the sirt1-p53-bax pathway[J].Virus Genes, 2015, 51 (3) :338-346.
|
|
[20]CHAO CC.Inhibition of apoptosis by oncogenic hepatitis B virus Xprotein:implications for the treatment of hepatocellular carcinoma[J].World J Hepatol, 2016, 8 (25) :1061-1066.
|
|
[21]ZHOU Q, LUI VW, YEO W.Targeting the PI3K/Akt/m TOR pathway in hepatocellular carcinoma[J].Future Oncol, 2011, 7 (10) :1149-1167.
|
|
[22]PELLEGRINO R, CALVISI DF, NEUMANN O, et al.EEF1A2 inactivates p53 via PI3K/AKT/m TOR-dependent stabilization of MDM4 in hepatocellular carcinoma[J].Hepatology, 2014, 59 (5) :1886-1899.
|
|
[23]ZHAO BX, ZHAO WX, WANG Y, et al.Connexin32 regulates hepatoma cell metastasis and proliferation via the p53 and Akt pathways[J].Oncotarget, 2015, 6 (12) :10116-10133.
|
|
[24]FAN YH, LIU JY, LIU D, et al.NSCA-1-a novel N-substituted coumalamide derivative-increases Adriamycin sensitivity in Hep G2/adriamycin cells through modulating Akt/GSK-3 signaling and p53-dependant apoptotic pathway[J].Environ Toxicol Pharmacol, 2017, 49:1-7.
|
|
[25]BRITO AF, ABRANTES AM, PINTO-COSTA C, et al.Hepatocellular carcinoma and chemotherapy:the role of p53[J].Chemotherapy, 2012, 58 (5) :381-386.
|
|
[26]LIU H, CHEN W, LIANG C, et al.WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation[J].Cancer Lett, 2015, 361 (2) :218-225.
|
|
[27]WEI WX, LEI ZQ, WANG K, et al.Current treatment for intermediate-stage hepatocellular carcinoma[J].Chin J Dig Surg, 2016, 15 (4) :407-410. (in Chinese) 尉文新, 雷正清, 王葵, 等.中期肝癌的治疗现状[J].中华消化外科杂志, 2016, 15 (4) :407-410.
|
|
[28]KUDO M.Targeted therapy for liver cancer:updated review in 2012[J].Curr Cancer Drug Targets, 2012, 12 (9) :1062-1072.
|
|
[29]MIYAHARA K, NOUSO K, YAMAMOTO K.Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age[J].World J Gastroenterol, 2014, 20 (15) :4151-4159.
|
|
[30]WEI JC, MENG FD, QU K, et al.Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing Fox M1[J].Acta Pharmacol Sin, 2015, 36 (2) :241-251.
|
|
[31]LI-WEBER M.Targeting apoptosis pathways in cancer by Chinese medicine[J].Cancer Letters, 2013, 332 (2) :304-312.
|
|
[32]HAN ZY, HAN Z, ZHU JF.Traditional Chinese medicine treatment of primary liver cancer[J].J Changchun Univ Chin Med, 2016, 32 (2) :426-429. (in Chinese) 韩中颖, 韩政, 祝峻峰.中医药治疗原发性肝癌临床研究进展[J].长春中医药大学学报, 2016, 32 (2) :426-429.
|
|
[33]ZHANG XL, YU H.Matrine inhibits diethylnitrosamine-induced HCC proliferation in rats through inducing apoptosis via p53, Bax-dependent caspase-3 activation pathway and down-regulating MLCK overexpression[J].Iran J Pharm Res, 2016, 15 (2) :491-499.
|
|
[34]MONTAZERI M, SADEGHIZADEH M, PILEHVAR-SOLTAN-AHMADI Y, et al.Dendrosomal curcumin nanoformulation modulate apoptosis-related genes and protein expression in hepatocarcinoma cell lines[J].Int J Pharm, 2016, 509 (1-2) :244-254.
|
|
[35]BI L, YAN XJ, CHEN WP, et al.Antihepatocellular carcinoma potential of tetramethylpyrazine induces cell cycle modulation and mitochondrial-dependent apoptosis:regulation of p53 signaling pathway in Hep G2 cells in vitro[J].Integr Cancer Ther, 2016, 15 (2) :226-236.
|
|
[36]LI YL, ZHANG JL, MIN D, et al.anticancer effects of 1, 3-dihydroxy-2-methylanthraquinone and the ethyl acetate fraction of hedyotis diffusa willd against Hep G2 carcinoma cells mediated via apoptosis[J].PLo S One, 2016, 11 (4) :e0151502.
|
|
[37]CHANG W, HE W, LI PP, et al.Protective effects of Celastrol on diethylnitrosamine-induced hepatocellular carcinoma in rats and its mechanisms[J].Eur J Pharmacol, 2016, 784:173-180.
|
|
[38]SUN YP, TAO CL, HUANG XM, et al.Metformin induces apoptosis of human hepatocellular carcinoma Hep G2 cells by activating an AMPK/p53/miR-23a/FOXA1 pathway[J].Onco Targets Ther, 2016, 9:2845-2853.
|
|
[39]ALUR I·, DODURGA Y, SECME M, et al.Anti-tumor effects of bemiparin in Hep G2 and MIA Pa Ca-2 cells[J].Gene, 2016, 585 (2) :241-246.
|
|
[40]VILLANUEVA-PAZ M, CORDERO MD, PAVON AD, et al.Amitriptyline induces mitophagy that precedes apoptosis in human Hep G2 cells[J].Genes Cancer, 2016, 7 (7-8) :260-277.
|
DownLoad: